N4 Pharma PLC Posting of Annual Report & Notice of AGM

RNS Number : 4170M

N4 Pharma PLC

29 April 2024

 

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Posting of Annual Report & Notice of AGM

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2023 and Notice of its Annual General Meeting ("AGM") have been posted to shareholders.

 

The AGM will be held at 11:00am on 23 May 2024 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

 

The Group's Annual Report and Accounts and the Notice of AGM are available on the Company's website: https://www.n4pharma.com/

 

 

For more information please contact:

 

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director	investors.n4pharma.com
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: [phone]
InvestorHub Engage with us directly at N4 Pharma Investor Hub	Sign up at investors.n4pharma.com   https://investors.n4pharma.com/link/4PKgJP

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NOASEASUUELSEIL